BCL-X(L)-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors.

Judd AS, Bawa B, Buck WR, Tao ZF, Li Y, Mitten MJ, Bruncko M, Catron N, Doherty G, Durbin KR, Enright B, Frey R, Haasch D, Haman S, Haight AR, Henriques TA, Holms J, Izeradjene K, Judge RA, Jenkins GJ, Kunzer A, Leverson JD, Martin RL, Mitra D, Mittelstadt S, Nelson L, Nimmer P, Palma J, Peterson R, Phillips DC, Ralston SL, Rosenberg SH, Shen X, Song X, Vaidya KS, Wang X, Wang J, Xiao Y, Zhang H, Zhang X, Blomme EA, Boghaert ER, Kalvass JC, Phillips A, Souers AJ

Open source

DOI: 10.1126/sciadv.ado7120
Published: 2024 Oct 4
Container: Science advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1126/sciadv.ado7120,
  title = {BCL-X(L)-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors.},
  author = {Judd AS and Bawa B and Buck WR and Tao ZF and Li Y and Mitten MJ and Bruncko M and Catron N and Doherty G and Durbin KR and Enright B and Frey R and Haasch D and Haman S and Haight AR and Henriques TA and Holms J and Izeradjene K and Judge RA and Jenkins GJ and Kunzer A and Leverson JD and Martin RL and Mitra D and Mittelstadt S and Nelson L and Nimmer P and Palma J and Peterson R and Phillips DC and Ralston SL and Rosenberg SH and Shen X and Song X and Vaidya KS and Wang X and Wang J and Xiao Y and Zhang H and Zhang X and Blomme EA and Boghaert ER and Kalvass JC and Phillips A and Souers AJ},
  year = {2024},
  journal = {Science advances},
  doi = {10.1126/sciadv.ado7120},
  url = {https://doi.org/10.1126/sciadv.ado7120}
}

RIS

TY  - JOUR
TI  - BCL-X(L)-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors.
AU  - Judd AS
AU  - Bawa B
AU  - Buck WR
AU  - Tao ZF
AU  - Li Y
AU  - Mitten MJ
AU  - Bruncko M
AU  - Catron N
AU  - Doherty G
AU  - Durbin KR
AU  - Enright B
AU  - Frey R
AU  - Haasch D
AU  - Haman S
AU  - Haight AR
AU  - Henriques TA
AU  - Holms J
AU  - Izeradjene K
AU  - Judge RA
AU  - Jenkins GJ
AU  - Kunzer A
AU  - Leverson JD
AU  - Martin RL
AU  - Mitra D
AU  - Mittelstadt S
AU  - Nelson L
AU  - Nimmer P
AU  - Palma J
AU  - Peterson R
AU  - Phillips DC
AU  - Ralston SL
AU  - Rosenberg SH
AU  - Shen X
AU  - Song X
AU  - Vaidya KS
AU  - Wang X
AU  - Wang J
AU  - Xiao Y
AU  - Zhang H
AU  - Zhang X
AU  - Blomme EA
AU  - Boghaert ER
AU  - Kalvass JC
AU  - Phillips A
AU  - Souers AJ
PY  - 2024
JO  - Science advances
DO  - 10.1126/sciadv.ado7120
UR  - https://doi.org/10.1126/sciadv.ado7120
ER  -

APA

AS, J., B, B., WR, B., ZF, T., Y, L., MJ, M., M, B., N, C., G, D., KR, D., B, E., R, F., D, H., S, H., AR, H., TA, H., J, H., K, I., RA, J., GJ, J., A, K., JD, L., RL, M., D, M., S, M., L, N., P, N., J, P., R, P., DC, P., SL, R., SH, R., X, S., X, S., KS, V., X, W., J, W., Y, X., H, Z., X, Z., EA, B., ER, B., JC, K., A, P., & AJ, S. (2024). BCL-X(L)-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors.. Science advances. https://doi.org/10.1126/sciadv.ado7120

Source records

pubmed · retrieved 2026-09-25T11:00:23.251Z